Niki Mariko, Kamata Masahiro, Tada Yayoi, Kubo Yoshiaki
Department of Dermatology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
J Dermatolog Treat. 2025 Dec;36(1):2555684. doi: 10.1080/09546634.2025.2555684. Epub 2025 Sep 7.
Baricitinib showed efficacy for alopecia areata (AA) in clinical trials, with real-world data supporting its short-term effectiveness. However, long-term data are limited. We assessed the effectiveness and safety of baricitinib in AA patients over one year and explored predictive factors.
We analyzed data from 27 AA patients treated with baricitinib at our hospital.
The majority (81%) had alopecia universalis, with a mean baseline SALT score of 93.9. Disease duration was positively correlated with the current AA episode's duration and negatively with serum TARC levels. At 3, 6, 9, and 12 months, 3.8%, 19.2%, 37%, and 58% of patients achieved a SALT score ≤20, respectively. The duration of the current AA episode at initiating baricitinib was correlated positively with absolute SALT score at 6 and 9 months, and negatively with the reduction rate of SALT score at 6 and 9 months. A shorter duration of the current episode (<4 years) was associated with better improvement in SALT scores at 6, 9, and 12 months compared to longer durations (≥4 years).
Baricitinib proved effective and safe for severe AA patients. The duration of the current AA episode is a key predictor of treatment success, highlighting the importance of early intervention.
巴瑞替尼在临床试验中显示出对斑秃（AA）有效，真实世界数据也支持其短期有效性。然而，长期数据有限。我们评估了巴瑞替尼在AA患者中超过一年的有效性和安全性，并探索了预测因素。
我们分析了在我院接受巴瑞替尼治疗的27例AA患者的数据。
大多数（81%）为全秃，平均基线SALT评分为93.9。病程与当前AA发作的持续时间呈正相关，与血清TARC水平呈负相关。在3、6、9和12个月时，分别有3.8%、19.2%、37%和58%的患者SALT评分≤20。开始使用巴瑞替尼时当前AA发作的持续时间与6和9个月时的绝对SALT评分呈正相关，与6和9个月时SALT评分的降低率呈负相关。与较长病程（≥4年）相比，当前发作持续时间较短（<4年）的患者在6、9和12个月时SALT评分改善更好。
巴瑞替尼对重度AA患者有效且安全。当前AA发作的持续时间是治疗成功的关键预测因素，突出了早期干预的重要性。
